Products
Providing High quality, Effective, Safe and Affordable Biosimilar Products to
Benefit More Patients and Create Societal Value in China
1. High Quality Production
Celltrion has cGMP biologics production facilities approved by FDA & EMA, and complied with the current global GMP regulations including Europe and United States
2. Successful International Launches
Products have been approved by EMA, FDA, and Japan, and launched in Europe, Korea, Japan with many patient usage experiences
3. Stable Supply
Celltrion's production facilities will secure steady supply of products to meet patients' treatment needs
4. Insurance Budget Saving
Significant savings to China Medical Insurance Fund with high quality and economic biosimilar alternatives
5. Societal/Patient Value
The introduction of products will increase treatment accessibility and alleviate the economic and mental burden of patients and their families
6. Real World Evidence
Celltrion has successfully launched biosimilar products around the world with rapid market share growth. Available real-world evidence has demonstrated efficacy and safety of the products
  • CT-P13/Remsima®
    INN (Reference): Infliximab (REMICADE)
    Major Indication: Rheumatoid Arthritis, IBD
    Approved by: FDA, EMA, MFDS and over 80 countries (not yet approved in China)
  • CT-P6/Herzuma®
    INN (Reference): Trastuzumab (HERCEPTIN)
    Major Indication: Breast Cancer, Gastric Cancer
    Approved by: EMA, MFDS, FDA, Japan (not yet approved in China)
  • CT-P10/Truxima®
    INN (Reference): Rituximab (RITUXAN)
    Major Indication: Non-Hodgkin's Lymphoma
    Approved by: EMA, MFDS, FDA (not yet approved in China)
Contact Us
Suite1202B, 12F, Tower 2, 1239 Century Avenue, Century Metropolis, Pudong District, Shanghai, PRC
Email: dingsai@vcellhealthcare.com /Career: HR@vcellhealthcare.com/Patient Recruitment: clinicaltrial@vcellhealthcare.com
©2019 Vcell Healthcare Limited 沪ICP备19024936号
Power By : A+T